Researchers Studying Universal Donor NK Cells in Combination with IV Drug Therapy in Patients With Relapsed or Refractory Neuroblastoma
Phase: Recruiting
First Posted: February
Condition(s): Neuroblastoma
NCT Number: NCT04211675 Other Study ID Number(s): STING
What Is the Purpose of This Study?
To study the safety, tolerability, and efficacy of a fixed dose of UD TGFβi NK cells in combination with standard irinotecan, temozolomide, and dinutuximab IV therapy.
Who Can Take Part in This Study?
People who may be eligible for this study:
- Have relapsed or refractory neuroblastoma.
- Are under 30 years old.
For a full list of eligibility requirements, visit https://clinicaltrials.gov/study/NCT04211675
What Will Happen During This Study?
- Participants will receive IV chemotherapy (temozolomide, dinutuximab, and dinutuximab) on days 1-5 of each cycle and one dose of NK cells on Day 8 of each cycle.
- Each cycle is 21 days long. Participants will receive up to 6 cycles.
Principal Investigator
Discover More Research
Explore additional studies relating to cell therapyYour Might Also Be Interested In
Neuroblastoma
Neuroblastoma is a rare cancer that develops from immature nerve cells. It most commonly arises in and around the adrenal glands, but can also develop in other areas of the body.
What Is Neuroblastoma?
Most commonly diagnosed before age 5 years, neuroblastoma is the most common solid tumor outside of the brain in children. The average age of a child diagnosed with neuroblastoma is about 18 months old.
Research and Clinical Care: How They Work Together to Treat Children
In this 700 Children's blog post for parents, Nationwide Children's highlights how clinical research and clinical care work together as a key part of our strategic plan to achieve the best outcomes for children. Before delving into these elements work together, the post covers the basics of clinical research.